Stockscreener 앱 받기
94.07
0.28%
-0.221
Revvity Inc 주식(RVTY)의 최신 뉴스
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - Reuters
Evercore ISI Adjusts Price Target on Revvity to $116 From $125 - marketscreener.com
Biotech Firm Revvity Reports Better-Than-Expected Earnings - Investopedia
Revvity's Steady Demand Lifts Q1 Results Above Expectations - Finimize
Revvity Q1 Earnings Surpass Street Estimates, Investors Cheer 2025 Revised Revenue Guidance - MSN
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Nasdaq
Life Science Tools Maker Revvity Delivers Strong Q1 Earnings Despite Evolving Macroeconomic Backdrop - Benzinga
Revvity (RVTY) Surpasses Q1 Estimates and Updates 2025 Outlook - GuruFocus
Revvity: Q1 Earnings Snapshot - Greenwich Time
Revvity, Inc. (RVTY) Implements Majority Voting Standard Followi - GuruFocus
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Revvity Announces Financial Results for the First Quarter of 202 - GuruFocus
Revvity beats Q1 estimates, shares jump 4% By Investing.com - Investing.com Nigeria
Revvity (RVTY) Exceeds Q1 Revenue Expectations with Strong Perfo - GuruFocus
REVVITY Earnings Results: $RVTY Reports Quarterly Earnings - Nasdaq
Revvity beats Q1 estimates, shares jump 4% - Investing.com Australia
(RVTY) Revvity Expects Full-Year 2025 Revenue Range $2.83B$2.87B, vs. FactSet Est of $2.83B - marketscreener.com
Revvity Announces Financial Results for the First Quarter of 2025 - Business Wire
Revvity (RVTY) Q1 Earnings Report Preview: What To Look For - The Globe and Mail
Revvity’s Quarterly Earnings Preview: What You Need to Know - MSN
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely? - MSN
Why Revvity (RVTY) Could Beat Earnings Estimates Again - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Calculating The Fair Value Of Revvity, Inc. (NYSE:RVTY) - simplywall.st
Earnings Preview For Revvity - Benzinga
Revvity Keeps Quarterly Dividend at $0.07 a Share, Payable August 8 to Holders of Record July 18 - marketscreener.com
Lobbying Update: $30,000 of REVVITY INC. lobbying was just disclosed - Nasdaq
Revvity Board Declares Quarterly Dividend - Business Wire
Revvity Board Declares Quarterly Dividend | RVTY Stock News - GuruFocus
Revvity Continues Steady Dividend Program: $0.07 Per Share Coming This August - Stock Titan
Revvity to Unveil VivoJect Image-guided Injection System at AACR - Genetic Engineering and Biotechnology News
Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation - Genetic Engineering and Biotechnology News
Revvity’s Quarterly Earnings Preview: What You Need To Know - Barchart.com
High Content Screening and Imaging Market Set for 8.4% CAGR Through 2029 - GlobeNewswire Inc.
Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | R - GuruFocus
Revvity Fuels the Future of Cancer Science with New Research Solutions - Business Wire
Assessing Revvity: Insights From 6 Financial Analysts - Benzinga
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline - Yahoo Finance
Revvity (RVTY) Price Target Cut by Baird Ahead of Q1 Results | RVTY Stock News - GuruFocus
Bernstein Adjusts Price Target on Revvity to $120 From $140, Maintains Market Perform Rating - marketscreener.com
Revvity price target lowered to $120 from $140 at Bernstein - TipRanks
Lab equipment giant ensnared in sprawling $300M fraud case over failed testing tools - Crain's Chicago Business
Revvity (RVTY) Faces Price Target Cut Amid Funding Concerns | RV - GuruFocus
Ex-Dividend Reminder: Revvity, Dime Community Bancshares and First Busey - Nasdaq
What Is Revvity, Inc.'s (NYSE:RVTY) Share Price Doing? - Yahoo Finance
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges - GuruFocus
BofA Securities Cuts Price Target on Revvity to $116 From $143, Maintains Buy Rating - MarketScreener
BofA Reduces Revvity (RVTY) Price Target Amid Policy Challenges | RVTY Stock News - GuruFocus
KeyBanc Lowers Price Target on Revvity to $135 From $145 - MarketScreener
Choosing a flexible digital platform for drug discovery - Scientific Computing World
Barclays Adjusts Revvity (RVTY) Price Target Ahead of Q1 Earnings | RVTY Stock News - GuruFocus
Barclays Adjusts Price Target on Revvity to $110 From $140 - MarketScreener
KeyBanc maintains Overweight rating on Revvity stock at $145 target - Investing.com Australia
KeyBanc maintains Overweight rating on Revvity stock at $145 target By Investing.com - Investing.com South Africa
0.90%
자본화:
|
볼륨(24시간):